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Multiorgan failure is a frequent complication in critically ill patients, especially those suffering from systemic inflammatory syndromes \[[@B1],[@B2]\]. The functional changes in the affected patients are known to affect primarily the lungs, the cardiovascular system as well as the kidneys. While our therapeutic efforts have therefore often been focused on these organ systems, it seems advisable to also include the gastrointestinal tract in the therapeutic management of critically ill patients \[[@B1]\]. Alterations in gastrointestinal motility are frequently found in such patients, leading to disturbances in nutrient absorption, induction of nausea and an increased risk of aspiration \[[@B1]\]. Furthermore, the gut has long been established as an important immune barrier, providing a safeguard against infectious complications \[[@B3]\]. For these reasons, tight clinical monitoring of gastrointestinal motility is central in the clinical management of critically ill patients, and the advantages of early enteral nutrition versus parenteral nutrient supplementation have been highlighted in numerous previous trials \[[@B3]\].

In the current issue of *Critical Care*, Dean and colleagues present a concise review that summarises the most important endocrine hormones secreted from the gut and discusses their functional alterations in critically ill patients \[[@B1]\]. Amongst those factors, the most prominent is certainly the incretin hormone glucagon-like peptide (GLP)-1, a 29-amino-acid peptide secreted from intestinal L cells in response to nutrient ingestion \[[@B4]\]. In healthy individuals, this hormone is partly responsible for the augmentation of insulin responses to glucose and meal ingestion \[[@B5]\]. In addition, GLP-1 might play a role in the so-called ileal brake mechanism; that is, the deceleration of gastric emptying and acid secretion induced by the presence of nutrients in the ileum \[[@B6]\]. There is also good evidence for a role of GLP-1 in the cardiovascular system as well as in the central nervous control of appetite and food intake \[[@B4],[@B7]\].

Owing to its potent glucose-lowering properties, two different types of GLP-1-based therapies have now become available for the treatment of type 2 diabetes. The GLP-1 analogues are injectable agonists at the GLP-1 receptor with a prolonged biological half life, whereas the DPP-4 inhibitors prevent the proteolytic degradation of GLP-1, thereby raising its endogenous plasma concentrations \[[@B8]\]. Because the secretion of GLP-1 is stimulated by the absorption of nutrients from the gut, reductions in GLP-1 plasma concentrations are often caused by alterations in gut motility and absorption \[[@B9]\]. Disturbances in GLP-1 plasma levels are therefore likely to occur in critically ill patients, which are prone to developing abnormal gastrointestinal motility. In particular, the release of incretin hormones is no longer stimulated in patients receiving total parenteral nutrition \[[@B10]\].

What are the potential consequences arising from impaired incretin hormone release in critically ill patients? Most obviously, the stimulation of insulin secretion would be diminished, whereas glucagon levels might increase. Also, the improvements in cardiac function observed during exogenous GLP-1 administration \[[@B11]\] might suggest deteriorations in cardiac functions in patients with low GLP-1 levels, although a role of endogenous GLP-1 in the cardiovascular system has not yet been fully established. On the other hand, reductions in GLP-1 plasma levels might also slightly increase appetite and promote gastric emptying, which appears to be rather desirable in critically ill patients.

In light of the potential reductions in GLP-1 concentrations in critically ill patients, and because of the potent glucose-lowering effects of GLP-1 in diabetic patients with no risk of inducing hypoglycaemia \[[@B12]\], the effects of acute intravenous infusions of GLP-1 have been examined in initial proof-of-concept studies in critically ill patients after abdominal surgery \[[@B13]\], after cardiac surgery \[[@B14]\], during parenteral nutrition \[[@B10]\] as well as during enteral feeding \[[@B15]\]. Collectively, these studies have suggested a beneficial role for GLP-1 treatment in critically ill patients.

When considering the exogenous administration of GLP-1 in such patients, however, it is still important to bear in mind that the gut also produces at least 30 to 50 other peptide hormones \[[@B16]\], the physiological functions of which are still not fully elucidated. While the exogenous administration of some of these hormones (for example, ghrelin, GLP-1, GLP-2) may provide certain benefits in terms of glucose homoeostasis, gastric emptying or intestinal epithelial regeneration, mimicking the physiological responses of all major gastrointestinal hormones in critically ill patients is certainly far from realistic. From a pragmatic point of view, the easiest way to normalise the secretion of gastrointestinal hormones in such patients is to provide enteral nutrition as early as possible.

Overall, the review article by Dean and colleagues provides a state-of-the-art overview of our knowledge about the changes in gastrointestinal hormone secretion and action in critically ill patients \[[@B1]\]. At the same time, the complexity of the gut\'s endocrine network and the multiple biological functions affected by gastrointestinal hormones clearly emphasise the need for further studies in this area in order to gain a better understanding of the biological functions of these hormones and their potential alterations in critically ill patients. Such future studies could then pave the way towards an implementation of gut hormone preparations in the acute management of critical illnesses.

Ultimately, the endocrine failure of the gastrointestinal tract may be considered alongside other endocrine insufficiencies in such patients, such as sympathoadrenal insufficiency \[[@B17]\]. Along these lines, future therapeutic strategies may then also include the substitution of gastrointestinal hormones in critically ill patients, similar to the substitution of corticosteroids in septic patients.
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